With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck’s Keytruda
With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda The Bristol-Myers Squibb-vs.-Merck match in melanoma is on. Bristol-Myers ($BMY) scored FDA approval for its cancer immunotherapy Opdivo (nivolumab) three months ahead ...